A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant

被引：0
|
作者：
Qu, J. [1 ]
Liu, L. [2 ]
Heng, J. [2 ]
Zhou, C. [2 ]
Xiong, Y. [2 ]
Jiang, W. [2 ]
Yang, N. [2 ]
机构：
[1] Hunan Prov Canc Hosp, Dept Lung Canc & Gastroenterol, Changsha, Hunan, Peoples R China
[2] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
133P
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [21] EGFR mutation status in cerebrospinal fluid of NSCLC patients who developed leptomeningeal metastasis after EGFR-TKI treatment
    Zhao, Jing
    Ye, Xin
    Sun, Yun
    Yang, Zhenfan
    Zhu, Guanshan
    Chen, Minjiang
    Zhong, Wei
    Xu, Yan
    Zhang, Li
    Li, Longyun
    Xiao, Yi
    Wang, Mengzhao
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
    Yu, Y.
    Yang, N.
    Zhang, Y.
    Zhang, H.
    Li, M.
    Yu, Q.
    Zhou, J.
    Hu, X.
    Fang, J.
    Zhao, H.
    Feng, J.
    Li, L.
    Shu, Y.
    Wang, X.
    Sun, M.
    Zhang, J.
    Li, M.
    Ren, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1553 - S1553
  • [23] Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for advanced NSCLC with EGFR-positive mutation patients: A systematic review
    Chen, S.
    Marcella, E.
    Susanto, B.
    Tandiono, J.
    Heriyanto, R. S.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S780
  • [24] Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study
    Baldacci, Simon
    Mazieres, Julien
    Tomasini, Pascale
    Girard, Nicolas
    Guisier, Florian
    Valette, Clarisse Audigier
    Monnet, Isabelle
    Wislez, Marie
    Perol, Maurice
    Do, Pascal
    Dansin, Eric
    Leduc, Charlotte
    Leprieur, Etienne Giroux
    Moro-Sibilot, Denis
    Kherrouche, Zoulika
    Labreuche, Julien
    Cortot, Alexis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1219 - S1220
  • [25] EGFR Mutation Testing and First Line Treatment of Patients With Advanced NSCLC and Positive EGFR Mutation Status - Results From a German Registry
    Eberhardt, W.
    Thomas, M.
    von der Schulenburg, J. M. Graf
    Dietel, M.
    Schirmacher, P.
    Gutendorf, B.
    Zirrgiebel, U.
    Schuette, W.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S636 - S636
  • [26] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [27] Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
    Zhou, Shujie
    Ren, Fei
    Meng, Xiangjiao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
    Wu, Yi-Long
    Soo, Ross Andrew
    Locatelli, Giuseppe
    Stammberger, Uz
    Scagliotti, Giorgio
    Park, Keunchil
    CANCER TREATMENT REVIEWS, 2017, 61 : 70 - 81
  • [29] Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation-positive NSCLC who failed in immediately previous EGFR-TKI therapy.
    Hirashima, Tomonori
    Azuma, Koichi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    Nishio, Makoto
    Hirata, Taizo
    Kubota, Kaoru
    Kasahara, Kazuo
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Suzuki, Kohei
    Akinaga, Shiro
    Nishio, Kazuto
    Mitsudomi, Tetsuya
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC
    Soo, R. A.
    Kim, D. W.
    Yang, J. C. H.
    Stammberger, U.
    Xiong, H.
    Ihling, C.
    Wu, Y. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S625 - S625
12345